Abbott receives fda clearance for its imaging technology using artificial intelligence for vessels in the heart

Abbott park, ill., aug. 3, 2021 /prnewswire/ -- abbott (nyse: abt) today announced it has received u.s. food and drug administration (fda) clearance for its latest optical coherence tomography (oct) imaging platform powered by the company's new ultreon software.

ABT Ratings Summary

ABT Quant Ranking